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ABSTRACT* 
Objective: The objective of this narrative review was 
to identify and describe the current policy, education 
and research related to community pharmacy and 
medication adherence in England. 
Methods: Medline, Embase, International 
Pharmaceutical Abstracts and Pharmline were used 
to search for relevant research articles. Current 
policy documents were identified via the websites of 
the Department of Health in England, the Royal 
Pharmaceutical Society of Great Britain, the 
National Pharmacy Association, the Pharmaceutical 
Services Negotiating Committee and NHS 
Employers. All pharmacy schools in England were 
contacted to obtain information about the 
adherence-related courses they provide to 
undergraduate and postgraduate pharmacy 
students. 
Results: National policies and guidelines in England 
are conducive to an increasing role for community 
pharmacists to support patients with medication 
adherence. Many pharmacy schools cover the issue 
of adherence in their undergraduate and 
postgraduate courses. Research in this area has 
tested the effectiveness of pharmacists providing 
adherence support in the form of compliance aids, 
education, involvement in discharge planning, and 
tailored interventions.  
Conclusion: In community pharmacy in England, 
current policy and funding arrangements suggest 
there is great scope for pharmacists to support 
patients with medication adherence. Further 
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CUMPLIMIENTO DE MEDICACIÓN Y 
FARMACIA COMUNITARIA: REVISIÓN DE 
LA EDUCACIÓN, POLÍTICA E 
INVESTIGACIÓN EN INGLATERRA 
 
RESUMEN 
Objetivo: El objetivo de esta revisión narrativa fue 
identificar y describir la política, educación e 
investigación actuales relacionadas con la farmacia 
comunitaria y el cumplimiento de la medicación en 
Inglaterra. 
Métodos: Se utilizaron Medline, Embase, 
International Pharmaceutical Abstracts y Pharmline 
para buscar artículos de investigación relevantes. 
Se identificaron los documentos políticos actuales a 
través de la página web del Departamento de Salud 
de Inglaterra, de la Royal Pharmaceutical Society 
de Gran Bretaña, de la Asociación Nacional de 
Farmacia, del Pharmaceutical Services Negotiating 
Committee y del NHS Employers. Se contactó con 
todas las facultades de farmacia en Inglaterra para 
obtener información sobre los cursos relacionados 
con el cumplimiento que proporcionaban a 
estudiantes de pre- y post-grado. 
Resultados: Las políticas nacionales y las guías en 
Inglaterra son conducentes a un mayor papel de los 
farmacéuticos comunitarios en el apoyo al 
cumplimiento de la medicación en pacientes. 
Muchas facultades de farmacia cubren la materia de 
cumplimiento de la medicación en sus cursos de 
pre- y post-grado. La investigación en esta área ha 
probado la efectividad de los farmacéuticos 
proporcionando apoyo al cumplimiento de la 
medicación a través de dispositivos de ayuda al 
cumplimiento, educación, participación en los 
planes al alta, y en intervenciones específicas. 
Conclusión: En la farmacia comunitaria en 
Inglaterra, la política  y las condiciones de 
financiación actuales sugieren que hay un gran 
interés por los farmacéuticos en apoyar a los 
pacientes en su cumplimiento con la medicación. 
Se necesita más investigación para identificar los 
abordajes más útiles, costo-efectivos y sostenibles 
en la práctica. 
 
Palabras clave: Adherencia a la medicación. 
Farmacéuticos. Educación farmacéutica. Reino 
Unido. 
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INTRODUCTION 
The World Health Organisation (WHO) referred to 
non-adherence as “a worldwide problem of striking 
magnitude” and improving adherence to medication 
has become a priority for health care researchers 
and policy makers.1 Researchers suggest that 30-
50% of patients do not take their medication for 
chronic conditions as prescribed.2,3 
The cost of non-adherence to patients is a missed 
opportunity for treatment gain and, if their condition 
worsens, a possible decline in their quality of life. 
Costs also arise from the perspective of the health 
care system; the cost of unused or unwanted 
medications exceeds GBP100 million annually.4 
Furthermore, the increased likelihood of 
hospitalisations and complications as a result of 
non-adherence can also increase costs.5,6 
In England, the community pharmacist has an 
increasingly important role to play in improving 
adherence and this is supported by current health 
policy. A recent White Paper (government policy 
document) from the Department of Health (DH) in 
England, called “Pharmacy in England – building on 
strengths, delivering the future”, sets out an 
innovative agenda for improving patient care by 
building on the existing strengths of community 
pharmacy to deliver further improvements in 
pharmacy services, such as support with medication 
adherence.4 
A recent survey, commissioned by the DH, found 
that 75% of people report to have visited a 
community pharmacy for health-related reasons 
within the last 6 months7 so pharmacists are well 
placed in the community to support patients with 
their medication use. According to an analysis of the 
Royal Pharmaceutical Society of Great Britain 
register in 2009, there were 38,051 registered 
pharmacists in England.8 Other figures show there 
are 10,475 community pharmacy premises in 
England.9 Community pharmacists work 
independently or as part of a multiple pharmacy 
group but all are independent contractors to the 
publicly funded National Health Service (NHS).  
The aim of this narrative review is to describe the 
policy, education and research related to community 
pharmacy and medication adherence in England. 
The objectives are: 1) To report on the 
undergraduate and postgraduate education about 
medication adherence in pharmacy schools in 
England; 2) To describe national policies and 
guidelines in England related to medication non-
adherence and the role of the community 
pharmacist; and 3) To identify and evaluate 
research related to the development and evaluation 
of community pharmacy adherence services in 
England. 
 
METHODS 
To identify relevant policy documents, hand 
searches were performed of the websites of the 
Department of Health (England), the Royal 
Pharmaceutical Society of Great Britain (RPSGB), 
the National Pharmacy Association (NPA), the 
Pharmaceutical Services Negotiating Committee 
(PSNC) and NHS Employers (NHSE).  
All pharmacy schools in England were contacted via 
email to obtain information about the adherence 
related education they provide to their 
undergraduate and postgraduate pharmacy 
students. Respondents were asked whether or not 
they provided adherence-related courses or lectures 
and, if so, to give details in an open-ended section. 
Research articles related to community pharmacy 
adherence services in England published in the last 
10 years were identified using the following 
databases: Medline, Embase; International 
Pharmaceutical Abstracts and Pharmline. We used 
the keywords [compliance or adherence], and 
[pharmacy or pharmacist] and [England or UK]. We 
also searched the reference lists of relevant papers 
in order to identify any additional studies.  
 
RESULTS 
Education 
Thirteen of the 21 pharmacy-teaching institutions in 
England responded. All pharmacy educational 
institutions in England offer a 4 year undergraduate 
Master of Pharmacy (MPharm) degree which is 
currently accredited by the Royal Pharmaceutical 
Society of Great Britain (RPSGB). On successful 
completion of the MPharm degree, students have to 
undertake a year of pre-registration training in an 
approved hospital or community pharmacy (or a 
split placement with six months spent in industry 
and six months in a hospital) before they can 
register as a pharmacist with the RPSGB. Some 
institutions also offer postgraduate pharmacy 
courses (Diploma and MSc) and short 
courses/modules for pharmacy technicians. 
Table 1 provides an overview of the current 
undergraduate and postgraduate education 
regarding medication adherence at each of these 
institutions. All institutions reported that they cover 
the concept of medication adherence in their 
undergraduate curriculum. Teaching and learning 
methods include lectures, practicals and workshops. 
The postgraduate and pharmacy technician courses 
also cover the topic of medication adherence. 
Policy 
National guidelines on medication adherence: 
In January 2009, the National Institute for Health 
and Clinical Excellence (NICE) published a clinical 
guideline called “Medicines adherence: involving 
patients in decisions about prescribed medicines 
and supporting adherence”.10 NICE is an 
independent organisation responsible for making 
recommendations about the treatment and care of 
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people with specific diseases and conditions in the 
NHS in England and Wales. 
The NICE medicines adherence guidelines are 
based on a review of the relevant evidence and 
recommendations are provided on how health care 
professionals (HCPs) can help patients make 
informed decisions about their medicines and how 
they can support patients to adhere to their 
prescribed treatment. NICE recommends three key 
ways in which this can be achieved: involving 
patients in decisions about their treatment, 
supporting adherence and reviewing medicines. 
Firstly, the recommendation, “Involving patients in 
decisions about their treatment”, is designed to help 
HCPs increase their understanding of the patients’ 
perspective regarding their treatment and to provide 
information about the condition and possible 
treatments.  
The second recommendation, “Supporting 
adherence”, calls on HCPs to support adherence by 
assessing patients’ adherence at appropriate times 
during the process of prescribing, dispensing and 
reviewing medicines. The aim is to identify when 
patients need additional information and support. 
HCPs should also consider whether further support 
or interventions are needed to help patients use 
their medicines most effectively. NICE guidelines 
emphasise how different approaches are needed 
depending on whether the non-adherence is 
intentional (related to beliefs, concerns, side effects 
etc) or unintentional (usually caused by practical 
problems). This is important because previous 
research has shown the underlying causes of these 
two types of non-adherence to be very different.11-13 
The third recommendation, “Reviewing medicines”, 
calls on HCPs to perform a regular review of a 
patient’s experience, needs and use of their 
medicines over time. The guidelines also highlight 
the need for improved communication between 
different health care professionals involved in a 
patient’s care, to maximise continuity of care and 
consistency of information provided. 
National policy and programmes specific to 
community pharmacy: 
The NICE guidelines are relevant for all HCPs 
involved in prescribing, dispensing and reviewing of 
medicines. To highlight the relevance for 
pharmacists, the Royal Pharmaceutical Society of 
Great Britain (RPSGB) published a reference sheet 
for pharmacists based on the NICE clinical 
guidelines.14 The pharmacy checklist that forms part 
of the two-page RPSGB reference sheet is shown in 
Table 2. The checklist highlights opportunities that 
pharmacists have to implement the guidelines at 
different steps of the prescribing, dispensing and 
reviewing process. 
The recent government White Paper, “Pharmacy in 
England: building on strengths – delivering the 
future”, discussed ways in which community 
pharmacists can provide services to support 
people’s adherence to medicines.4 Medicines Use 
Review (MURs) and Repeat Dispensing are cited as 
key opportunities for community pharmacists to 
intervene in supporting patients with the safe and 
effective use of their medicines. The community 
pharmacy contractual framework in England was 
revised in April 2005 to allow pharmacists to be 
reimbursed for these additional “advanced” and 
“enhanced” services.15 The new framework has 
three different levels of services: 
- Essential services: these must be provided by all 
contractors, e.g. dispensing and medicines 
waste disposal. 
- Advanced services: these can be provided by all 
pharmacy contractors who have the necessary 
accreditation requirements (related to either the 
pharmacist or the pharmacy premises), e.g. 
MURs. 
- Enhanced services: these are commissioned by 
primary care trusts to meet specific local 
healthcare needs, e.g. disease-specific 
medicines management, smoking cessation 
services. 
The Medicines Use Review service is a structured 
meeting between an accredited pharmacist and a 
patient, to identify any problems a patient may be 
experiencing with their medicines and, where 
necessary, to provide information and support to 
improve the patient’s knowledge, understanding and 
use of their prescribed medicines. Research has 
been done to assess the uptake of MURs by 
community pharmacists16 and pharmacists’ attitudes 
towards performing them17, but no studies have yet 
evaluated whether MURs improve adherence to 
medication. The Department of Health recognises 
that this is an important priority for further research.4 
The repeat dispensing scheme allows patients to 
receive up to a 12 month supply of their prescribed 
medicines directly from their community pharmacy. 
Where this was previously done via the patient’s 
general practitioner (GP), this now gives 
pharmacists the opportunity to check on how a 
patient is experiencing their medicines and whether 
they need further support with adhering to their 
treatment recommendations. 
The pharmacy White Paper also highlights the 
potential to provide additional adherence support 
when patients are starting a new prescription for a 
long term condition, such as hypertension or high 
cholesterol. Furthermore, Primary Care Trusts 
(PCTs), the local National Health Service 
organisations responsible for planning and funding 
primary care services, are also able to commission 
extra adherence services from community 
pharmacists to address issues specific to their local 
population.15 Information on the extent to which 
these services are actually commissioned in 
practice is hard to identify. However, a recently 
launched initiative, called “Motivation for Medicines 
adherence service (M4M)”, from an organisation 
called NPC Plus is an example of how pharmacists 
can deliver and be reimbursed for these services in 
practice.18 M4M provides the resources that a 
Primary Care Trust needs to commission a 
pharmacy adherence service that is customised to 
their local area. The training in therapeutics and 
adherence support they provide is designed to 
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prepare community pharmacists to deliver planned, 
structured M4M consultations with patients that will 
improve medication adherence. NPC Plus is a 
collaboration between the National Prescribing 
Centre and Keele University in England.  
The scope of pharmacy involvement in supporting 
medicines adherence is likely to widen as the 
pharmacy white paper stated “The Government 
considers further work is needed to strengthen the 
commissioning of services to support adherence to 
medicines and will therefore take forward, in 
partnership with interested parties, discussions on 
appropriate measures”.4 
Research 
From the literature search, adherence research 
studies in community pharmacy in England were 
related to either: a) compliance aids, b) patient 
education, c) community pharmacy involvement in 
discharge planning or d) patient-tailored 
interventions. Table 3 provides a summary of the 
eight studies identified (reported in nine research 
articles). 
Compliance aids: 
Mulitcompartment compliance aids (MCA) are 
issued to patients to make it easier for them to take 
their medication and improve adherence. The aids 
are divided into 7 days and each day is divided into 
four or more sections representing dosing times. 
Medication is dispensed into the correct 
corresponding compartments. In the UK, the 
available compliance aids vary in size and structure; 
some being disposable and others being reusable.19 
Some devices have multiple medicines in one 
compartment whereas others have only single 
medicines in each compartment. 
Three studies have addressed the use of 
compliance aids in England, the first consisted of a 
pharmacist (n=123) and patient survey (n=61) 
assessing how MCA are used in primary care20, the 
second was a survey of the use of MCA in 
secondary care in the UK and their transfer to 
primary care19 and the third was an exploratory 
controlled matched study to assess the effects of 
introducing MCA in frail elderly patients in one area 
of England.21 The results below focus on the use of 
MCA in community pharmacy settings. 
The primary care survey by Nunney and Raynor, 
conducted in one area of England, found that an 
average of 11 patients per pharmacy were receiving 
their medicines in MCAs.20 When these findings are 
extrapolated to the UK population this suggested 
that over 100,000 patients living in their own homes 
have medicines dispensed in MCAs. Processes for 
dispensing in MCA and the amount of patient 
contact varied between pharmacies.20 Pharmacists 
reported that general practitioners (GPs) and 
hospital staff were the most likely to initiate a 
request for an MCA, followed by carers and social 
service staff, with pharmacists being the least likely. 
Half the pharmacists reported that they would then 
visit the patient to assess the appropriateness of an 
MCA but the other half would not. Further to this, 
many patients had little contact with the GP or 
pharmacist with the majority of patients having their 
medication ordered by the pharmacist and nearly 
half having it delivered to their home by a person 
other than a healthcare professional.  
The effectiveness of MCA in increasing adherence 
has been studied very little in England. None of the 
three MCA studies reviewed here included a direct 
measure of adherence. In the survey by Nunney 
and Raynor, the research pharmacist carried out a 
subjective assessment and suggested that 29 out of 
61 patients would be able to cope well or 
reasonably well without an MCA. Twenty two 
percent of patients said they would be able to take 
their medication if it was dispensed in conventional 
containers and 18% said they had difficulty using 
the device. In the controlled matched study by 
Ryan-Woolley and Rees, medication wastage was 
reduced from 18.1% pre study to 1% 12 months 
after a change from conventional packaging to an 
MCA.21 However, data on wastage was not 
available for the control group. This may reflect the 
fact that it is easier to monitor medication in an 
MCA. A quarter of patients surveyed by Nunney and 
Raynor reported that the MCA allowed them to see 
if they had forgotten a dose.  
However, despite a lack of evidence on 
effectiveness, GPs, pharmacists and patients have 
all expressed positive views of multicompartment 
compliance aids. In the study by Ryan-Woolley and 
Rees, half the GPs interviewed (n=4) attributed the 
MCA to improved communication with patients 
during consultations. The pharmacists (n=2) 
indicated an increased level of professional 
satisfaction as a direct consequence of supplying 
the MCA. All intervention group patients (n=31) 
stated that they found it easy to remember to take 
their prescribed medication at the correct time as a 
result of the MCA. In the survey by Nunney and 
Raynor over 90% (n=52) of patients said that the 
MCA was much better than ordinary bottles.20 
Remuneration issues were raised in all three 
studies. Nunney and Raynor found the majority of 
pharmacists requested 7 day prescriptions in order 
to get remuneration for dispensing in MCA.20 Only 
one third of hospital pharmacists initiating MCA 
stated that they knew the local funding 
arrangements for MCAs once patients were living 
back in the community.19 The most commonly 
reported method of funding was the use of 7 day 
prescriptions, followed by dispensing fees for MCA, 
followed by the patients themselves. Pharmacists 
supplying MCA in the controlled trial expressed 
concerns about additional time and costs 
associated with supplying MCA.21 
Education: 
Little research in England has evaluated 
educational interventions alone by community 
pharmacists. A before and after study, in three 
areas of England, evaluated a community 
pharmacist intervention to increase adherence to 
effective use of emollients in children with 
eczema.22 Adherence was found to increase after 
the intervention but this result was not tested for 
statistical significance. There was a small statistical 
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difference in one of the clinical outcomes measured 
(itch and irritability). However, convenience 
sampling was used in a very specific population 
group and the results are not generalisable. 
Community pharmacy involvement in discharge: 
Data regarding the effectiveness of community 
pharmacy involvement in discharge in England is 
also limited. One intervention included community 
pharmacy domiciliary visits as part of a pharmacy 
discharge plan.23 The intervention had no effect on 
any of the study outcomes including re-admission to 
hospital, number of deaths, attendance at 
appointments, general well being, satisfaction with 
the service and knowledge and adherence to 
prescribed medication. However, the community 
pharmacy service was only one part of the 
intervention and data were not captured on what 
pharmacists actually did at the visits. 
Tailored interventions: 
Three studies, reported in four papers, have 
evaluated the effect of patient tailored interventions 
on adherence and all have shown positive 
outcomes.24-27 In these studies, pharmacists 
assessed the patients’ adherence related problems 
and tailored the action they took according to the 
patient’s responses. Blenkinsopp et al carried out a 
randomised controlled trial for patients with 
hypertension.24 Following the patient tailored 
adherence intervention, there were statistically 
significant increases in blood pressure control, self 
reported adherence and prescription refill amongst 
the intervention group when compared to the control 
group. Raynor et al carried out a before and after 
study for elderly patients and found that after the 
tailored adherence intervention the number of 
patients with medication related problems and the 
number of patients who reported non-adherence 
significantly fell.25 The intervention was also found 
to result in projected savings in costs per patient per 
year. Clifford et al carried out a randomised 
controlled trial of a tailored adherence intervention 
for patients starting new medication for a chronic 
condition and found that both medication-related 
problems and self reported non-adherence were 
significantly lower in the intervention than the 
control group.26 An economic analysis was also 
included and the intervention was found to be cost 
effective compared to usual care.27  
 
DISCUSSION 
The aim of this narrative review was to describe the 
policy, education and research related to community 
pharmacy and medication adherence in England. 
The results show that there are national policies 
which support the role of community pharmacists in 
activities that facilitate adherence to medication. 
Furthermore, reports from educational institutions 
show that this important topic is covered during the 
training of undergraduate pharmacy students. 
Research evidence shows that a range of 
community pharmacy-related interventions have 
been developed to improve medication adherence, 
but there is still limited evidence on the 
effectiveness and cost-effectiveness of these 
approaches.  
Taken together, the NICE guidelines on medication 
adherence10 and the Department of Health White 
Paper on the future of pharmacy4, shows that the 
policy context is highly conducive to community 
pharmacists in England adopting roles to support 
patients with their medication use, for example, via 
Medicines Use Reviews (MURs) and repeat 
dispensing. Furthermore, there is an increasing 
opportunity for more effective working relationships 
between community pharmacists and other primary 
care services which could lead to an enhanced 
ability to influence medication adherence. In 2010, 
NHS Employers, the British Medical Association’s 
General Practitioners Committee (GPC) and the 
Pharmaceutical Services Negotiating Committee 
(PSNC) developed and published two guides to 
support general practitioners and community 
pharmacists in finding new ways of working 
together.28,29 Improved collaborative relationships 
are likely to increase the likelihood of delivering 
effective services to support patients with their 
medication adherence – e.g. better communication 
and consistency of information and advice about 
prescribed medicines. 
In terms of educating pharmacists about adherence, 
all of the educational institutions who responded 
reported that they cover the topic of 
adherence/compliance in their undergraduate 
curriculum. A range of teaching methods were 
reported to be used, including lectures, workshops 
and practicals. Two institutions reported using a 
health psychologist to teach this component, which 
points to a growing multi-disciplinary nature of 
teaching and learning activities in pharmacy 
practice in England. As several institutions did not 
respond and this was only a brief self-report survey, 
further investigation is needed to examine whether 
pharmacy education is commensurate with the new 
roles that are available for community pharmacists 
to provide medication adherence-related support. 
For new services to be successful, it is crucial to 
ensure that pharmacists feel competent and skilled 
in delivering them. Pharmacy education needs to 
provide pharmacists with an understanding of the 
often complex issues underlying patients’ reasons 
for non-adherence.3 
In England, research to evaluate the effectiveness 
of community pharmacists’ efforts to support 
patients with adherence is relatively limited. There is 
a specific lack of studies investigating the 
effectiveness of compliance aids on improving 
adherence, although this is a commonly used 
intervention in practice. Interventions that are 
grounded in theory and tailored to the patient have 
been shown to improve adherence and be cost-
effective and they may be the way forward. 
However, further research is needed to evaluate 
these interventions on a larger scale and with a 
longer follow up period. 
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CONCLUSIONS 
Non-adherence to medication is a substantial 
problem which has consequences for patients and 
the health care system. Services to improve 
medication adherence have the potential to improve 
patients’ health and quality of life and to reduce 
health care costs. In England, community pharmacy 
policy and funding arrangements show that there is 
great scope for pharmacists to support patients with 
medication adherence. Further research is 
necessary to identify which approach is the most 
successful, cost-effective and sustainable. 
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Table 1.  Undergraduate and postgraduate pharmacy education in England regarding medication adherence. 
University Undergraduate (MPharm) Postgraduate/other 
Aston Pharmacy School, Aston University Concepts of adherence taught in workshops in years 2, 3 and 4. Concepts of adherence are taught in lectures on the Diploma in 
Clinical Pharmacy and the Prescribing certificate. 
Department of Pharmacy and Pharmacology 
at the University of Bath 
Five lectures during year 2 on intentional/unintentional non-adherence, use of 
compliance aids and concordance. 
Topics: concordance; teaching communication and consultation 
skills; involving patients in decisions about their medicines. 
Bradford School of Pharmacy, University of 
Bradford 
Lecture and workshop in year 3 on medication adherence. Not covered. 
School of Pharmacy and Biomolecular 
Sciences, University of Brighton 
Two lectures in year 1, delivered by a health psychologist.  Lecture 1: Why 
people don’t take their medicines as prescribed? What are the physical and 
psychological factors? How do illness beliefs relate to treatment beliefs? What 
beliefs do people have about medications? Lecture 2: How to measure 
adherence and how to improve a patient’s adherence. 
Consultation skills practicals: sessions are introduced using non-adherence as an 
example of why the consultation process is important. 
Prescribing course: a 3 hour session on adherence. 
Leicester School of Pharmacy, DeMontfort 
University 
Discussion of adherence is integrated throughout all four years. E.g. problem-
based learning sessions on responding to symptoms and sessions on Medicines 
Use Review (MUR). 
Diploma in Clinical Pharmacy: the discussion of adherence is 
included in one of the modules. 
Prescribing course: the discussion of adherence is included in 
sessions related to training to deliver Medicines Use Review.   
The School of Pharmacy, University of 
London 
Two lectures in years 2 and 4, delivered by a health psychologist that cover the 
following issues: definitions of adherence, compliance and concordance; 
understanding why patients are non-adherent to prescribed medicines; identifying 
ways in which community pharmacists can improve medication adherence. 
MSc in Clinical Pharmacy, International Practice and Policy (for 
international pharmacy students): a 3 hour workshop on 
adherence is delivered (covering the same issues as the 
undergraduate lectures). 
Department of Pharmacy, King’s College 
London 
Lectures and consultation skills workshops in years 1, 2 and 3 which use a 
consultation framework based on the “perceptions and practicalities” model by 
Rob Horne.3  Simulated patients are used to support this teaching. 
Short course on self-management in diabetes using a patient-
centred model of care.  Consists of theory and practical 
sessions. 
School of Pharmacy and Pharmaceutical 
Sciences, University of Manchester 
Two lectures in year 1 on adherence and six lectures in year 2 related to self-
care. Hospital visits and care-planning exercises in years 3 and 4 also explore 
aspects of adherence. 
Diploma in Clinical and Health Services Pharmacy: half day 
session on lay perspectives of adherence. 
School of Pharmacy, University of Nottingham One lecture on adherence in year 2 during the professional skills course.  Also, 
mentioned throughout clinical teaching and features in the community and 
hospital visit workbooks.  An Objective Structured Clinical Examination (OSCE), 
using video clips of pharmacist-patient scenarios regarding adherence, is used 
for assessment. 
Not applicable to the postgraduate courses. 
School of Pharmacy and Biomedical 
Sciences, University of Portsmouth 
Year 1: introduction of the concepts of compliance, concordance and adherence.   
Year 2: development of the above through communication and counselling 
studies. Year 3: medicines adherence covered in both primary and secondary 
care lectures. Year 4: further development in modules covering preparation for 
professional practice and therapeutics. In some years, MPharm projects may 
include adherence as a feature of study. 
Foundation degree in Medicines Management (for technicians): 
several sessions on medication adherence. 
School of Pharmacy and Biomedical 
Sciences, University of Central Lancashire 
Communication skills lecture on adherence/compliance/concordance in years 1 
and 2.  Lectures and workshops in year 3 in the Therapeutics & Prescribing 
module.  Lectures in year 4 in the Clinical Pharmacy & Pharmaceutical Care 
module and Cancer Management and Therapy module. 
Diploma in Clinical Pharmacy Practice: adherence covered as a 
topic of discussion. 
Table 1.  Undergraduate and postgraduate pharmacy education in England regarding medication adherence. 
University Undergraduate (MPharm) Postgraduate/other 
University of Reading Lectures in years 1 and 2 on adherence, compliance, concordance.  In year 3, 
adherence is covered under the ethics course and a module on “Social 
Pharmacy” which examines reasons behind decisions that patients make about 
their medication.  Also covered in sessions on risk management in year 4. 
Not at present. 
University of Wolverhampton The theory of adherence is introduced in year 1 and then built on in year 2 where 
the issue of adherence, compliance and concordance are covered in more depth.  
Practicals also allow students to counsel patients from an adherence perspective. 
Not at present (no postgraduate provision yet as this is a new 
School of Pharmacy in England). 
 
 
Table 2.  Pharmacy checklist from the Royal Pharmaceutical Society of Great Britain reference sheet for pharmacists from 
the NICE Clinical Guideline 76: Medicines Adherence.9 
• Adapt your consultation style to each patient’s needs. 
• Establish the level of involvement the patient wants in decisions about treatment with medicines; encourage and 
support patients, families and carers to keep an up-to-date list of prescription and non-prescription medicines, and 
allergies or adverse reactions. 
• Establish the patient’s perspective by asking what he/she knows and believes about a medicine.  Discuss the aim of 
the treatment and any concerns they may have before prescribing and when reviewing. 
• Provide information, check understanding and reinforce information; signpost to sources of reliable information and 
support. 
• Routinely assess adherence in a non-judgmental way; use pharmacy patient medication records (PMRs) and return 
of unused medicines to identify non-adherence and patients needing support. 
• Tailor any intervention to increase adherence (information, discussion or practical) to the patient’s specific needs. 
• Enquire about adherence during medicines use review (MUR) and medicines reconciliation. 
• Ensure that information arising during the prescribing, dispensing or reviewing of a patient’s medicines is 
communicated both to patients and other healthcare providers involved in the patient’s care. 
• Ensure that patient confidentiality is not breached. 
 
 Table 3.  A summary of studies from England involving community pharmacy and adherence interventions or devices. 
Authors and 
date 
Aims Pharmacy 
Service/Intervention 
Methods Main measures Outcomes/main findings 
Green & 
McCloskey 
(2005)19 
To describe and 
characterise the 
provision of 
multicompartment 
compliance aids and 
medicine reminder charts 
in UK hospitals; to 
investigate the transfer of 
information about these 
between secondary and 
primary care and to 
investigate methods of 
remuneration for MCA 
supply in primary care 
MCAs • Survey 
• 160 dispensary managers 
at acute hospitals 
• Community pharmacy 
related questions included 
funding for MCAs and 
communication between the 
hospital and community 
pharmacist 
• Funding for MCA by community pharmacists was 
reported to be unknown (61%), 7 day prescriptions 
(28.4%), MCA fees (9%), the patient (2%) 
• Information about the MCA was reported to be 
communicated to the patient’s community pharmacist 
by 66 (49.2%) hospitals; of these, various methods of 
communicating this information included telephone call 
(52%), fax (45%), letter for patient to take to community 
pharmacy (17%), letter mailed directly to community 
pharmacy (14%) 
Nunney & 
Raynor 
(2001)20 
To assess the scale of 
dispensing in compliance 
aids to patients at home, 
how community 
pharmacists provide this 
service and whether 
patients’ needs are met 
MCAs • Survey 
• 123 community 
pharmacists in Leeds, 
England 
• 56 patients currently using 
compliance aids 
• Self-completion 
questionnaire to all 
pharmacists in the Leeds 
Health Authority 
• Administered questionnaire 
to 10 pharmacists who 
provide MCAs 
• Administered questionnaire 
to all patients from the 10 
selected pharmacies  
• 95 (77%) of all pharmacists used MCAs  
• General practitioners and hospital staff were the main 
initiators of requests for an MCA 
• 10 (18%) patients had difficulty using the MCA device   
• 52 (93%) patients thought the MCA was better than 
conventional containers 
• 22 (39%) of patients thought they would be able to 
remember to take their medicines if still in conventional 
containers 
Ryan-Woolley 
& Rees 
(2005)21 
To assess medication 
wastage using a 
“medicines organiser 
(MO)” 
MCAs • Exploratory controlled-
matched study 
• 62 sheltered housing 
residents aged 60 or over 
in the North West of 
England 
• Intervention group: 
received MO 
• Control group: standard 
packaging 
• Wastage patterns of any 
unused medicines returned 
to community pharmacists by 
the study participants up to 
12 months follow-up 
• Intervention group wastage reduced from 18.1% 
baseline to 1% at 12 months (no statistical significance 
reported) 
• No data available for control group participants as they 
did not return any unused medicines to the pharmacist.   
Table 3.  A summary of studies from England involving community pharmacy and adherence interventions or devices. 
Authors and 
date 
Aims Pharmacy 
Service/Intervention 
Methods Main measures Outcomes/main findings 
Carr et al. 
(2007)22 
To determine the 
effectiveness of a 
community pharmacist 
intervention to promote 
effective use of 
emollients in children 
with atopic eczema 
Education • Before and after study 
• 50 children aged 1 – 7 with 
eczema 
• Telephone-administered 
questionnaire 
• Primary outcome: current 
severity of the symptoms 
(itch, irritability, sleep 
disturbance and skin 
appearance) 
• Increase in correct application of creams (significance 
not reported) 
• Small significant reduction in itch (p=0.001) and 
irritability (p=0.006) but little reduction in sleep 
deprivation (p=0.44) or skin appearance (p=0.09) 
Nazareth et al. 
(2001)23 
To investigate the 
effectiveness of a 
pharmacy discharge plan 
in elderly hospitalised 
patients 
Community pharmacy 
involvement in 
discharge 
• Randomised controlled trial 
• 362 patients aged 75 or 
over on 4 or more 
medicines who had been 
discharged from hospital 
(181 patients in the 
intervention group and 181 
in the control group) 
• Primary outcome: 
readmission to hospital 
• Secondary outcomes 
included adherence, 
assessed via a semi-
structured interview. 
• Other secondary outcomes: 
number of deaths, 
attendance at hospital 
outpatient clinics and general 
practice, global patient well-
being, satisfaction with the 
service, knowledge about 
medication 
• No significant differences between the intervention and 
control groups in readmission to hospital at 3 months 
(39% vs. 39.2%, respectively, difference = 0.18 
(95%CI: -10.6 to 10.2) or 6 months (27.9% vs. 28.4%, 
respectively, difference = 0.54 (95%CI: -11 to 9.9%) 
• No significant difference in mean (SD) adherence 
scores between intervention and control group patients 
at 3 months [0.75 (0.3) vs. 0.75 (0.28), respectively] or 
6 months [0.78 (0.3) vs. 0.78 (0.3), respectively) 
Blenkinsopp et 
al. (2000)24 
To assess the effect of a 
patient-centred 
intervention by 
community pharmacists 
on adherence to 
treatment for 
hypertension 
Tailored intervention • Randomised controlled trial 
• 20 community pharmacy 
sites (11 intervention and 9 
controls) in one health 
authority in England 
• 180 patients with 
hypertension (101 
intervention and 79 control) 
• Blood pressure (BP) control 
• Self-reported adherence, 
measured using a modified 
version of the Medication 
Adherence Report Scale 
(MARS).30 
• Patient satisfaction with 
pharmaceutical services, 
based on an adapted version 
of a scale developed in the 
United States by MacKeigan 
and Larson.31,32 
• For patients whose BP was uncontrolled prior to the 
study (n=28 in intervention group and n=35 in the 
control group), intervention group patients were more 
likely to have improved control at follow up than control 
group patients: 10 (35.7%) vs. 6 (17.1%), respectively 
(p <0.05) 
• Self reported adherence was significantly higher in the 
intervention group compared to control group; 62.9% 
vs. 50%, respectively (p <0.05) 
• An increased level of satisfaction with pharmacy 
services was reported by intervention patients 
regarding the “explanation” and “consideration” aspects 
of their pharmacist’s intervention 
Table 3.  A summary of studies from England involving community pharmacy and adherence interventions or devices. 
Authors and 
date 
Aims Pharmacy 
Service/Intervention 
Methods Main measures Outcomes/main findings 
Raynor et al. 
(2000)25 
To develop and evaluate 
an adherence support 
service by community 
pharmacists for elderly 
patients living at home 
Tailored intervention • Before and after study 
• 6 community pharmacists 
in the city of Leeds, 
England 
• 143 patients aged 65 or 
over, prescribed 4 or more 
medicines and living alone 
• Number of prescribed 
regular medicines 
• Knowledge of purpose of 
medicines 
• Number and nature of 
medicine-related problems 
• Self-reported adherence 
measured using items 
developed by Horne30 and 
Morisky.33 
• Cost of medication 
• A significant reduction in the number of patients who 
reported one or more medicine-related problems at 
follow-up from 94% to 58% (P<0.001) 
• The proportion of patients responding “rarely” or 
“never” to the five statements about non-adherence 
increased from 62% to 86% (p<0.001) 
• The number of patients with medication related 
problems was significantly reduced and self reported 
adherence significantly increased.  The cost of 
medication fell more than the cost of the pharmacist 
providing the service 
Clifford et al. 
(2006)26 
 
To assess the effect of 
pharmacists giving 
advice to meet patients’ 
needs after starting a 
new medicine for a 
chronic condition 
Tailored intervention • Randomised controlled trial 
• 500 patients 
• Patients aged 75 or over 
with a first prescription for 
a medication for stroke, 
cardiovascular disease, 
asthma, diabetes or 
arthritis 
• Primary outcome: self-
reported adherence (defined 
as missing at least one dose 
of the new medicine within 
the last 7 days) 
• Secondary outcomes 
included: number of 
medicine-related problems 
and beliefs about the 
medicine (the latter 
assessed using the Beliefs 
about Medicines 
Questionnaire)34 
• Non-adherence was significantly lower in the 
intervention group (9%) compared to the control (16%), 
p=0.032 
• Medication related problems were significantly lower in 
the intervention group (23%) compared to the control 
group (34%), p=0.021 
• Beliefs about medicines were more positive in the 
intervention group patients compared to control; mean 
scores 5 vs. 3.5, respectively (p=0.007)  
Elliott et al. 
(2008)27 
To assess the cost-
effectiveness of 
pharmacists giving 
advice via telephone to 
patients receiving a new 
medicine for a chronic 
condition 
Tailored intervention As per the Clifford et al study 
above 
• Outcome measures as per 
the Clifford et al study above 
• NHS resource use data 
(NHS contact, pharmacist 
training and time) were 
collected for each patient 6 
weeks after the intervention 
(unit costs for 2004/5 were 
used). 
• Incremental cost 
effectiveness ratios (ICERS) 
were generated 
• The intervention was cost effective compared to the 
control group 
• Mean total patient costs at follow-up (median, range) 
were intervention group: GBP187.7 (40.6, 4.2-2484.3); 
control group: GBP282.8 (42, 0-3804), p<0.0001 
Key: MO = Medicines Organiser, MCA = Multicompartment Compliance Aid 
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